BET抑制剂INCB054329降低同源重组效率并增强PARP抑制剂在卵巢癌中的活性
该研究以同源重组(HR)功能正常的卵巢癌细胞系及SKOV-3和患者来源异种移植瘤为对象,检测BRD4靶向siRNA、新型BET抑制剂(INCB054329、INCB057643)及已知BET抑制剂JQ1与PARP抑制剂(奥拉帕利、芦卡帕利)联用效果。结果显示BET抑制剂降低BRCA1和RAD51表达与功能、降低HR报告活性,并增敏奥拉帕利诱导的生长抑制、DNA损伤与凋亡,所有测试BET抑制剂与PARP抑制剂均显示协同作用。
要点
- BET抑制剂或BRD4 siRNA降低BRCA1和RAD51表达与功能,降低HR报告活性。
- BET抑制剂增敏卵巢癌细胞对奥拉帕利诱导的生长抑制、DNA损伤和凋亡。
- 所有测试BET抑制剂与PARP抑制剂联用均观察到协同作用。
核心结论
- 作者认为结果提供了强有力依据,支持使用BET抑制剂将PARP抑制剂的疗效扩展至HR功能正常的卵巢肿瘤,并可能使大量被诊断为此类难治性疾病的女性获益。
研究设计与样本
- 体外研究使用HR功能正常的卵巢癌细胞系OVCAR-3、OVCAR-4、SKOV-3和UWB1.289+BRCA1,分别以BRD4靶向siRNA、新型BET抑制剂INCB054329和INCB057643、已知BET抑制剂JQ1及PARP抑制剂奥拉帕利和芦卡帕利处理。
- 体内研究使用SKOV-3和卵巢癌患者来源异种移植瘤模型评估肿瘤生长。
- 细胞生长与活力采用磺酰罗丹明B法检测,DNA损伤与修复、凋亡和增殖标志物采用免疫荧光和蛋白质印迹评估。
主要发现
- 在培养细胞中,BRD4 siRNA或INCB054329降低BRCA1和RAD51的表达与功能,降低HR报告活性,并增敏奥拉帕利诱导的生长抑制、DNA损伤诱导和凋亡。
- 所有测试的BET抑制剂与PARP抑制剂之间均观察到协同作用。
- INCB054329与奥拉帕利协同抑制异种移植瘤生长,伴BRCA1表达和增殖降低、凋亡和DNA损伤增加。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Homologous recombination (HR)-proficient ovarian tumors have poorer clinical outcomes and show resistance to poly ADP ribose polymerase inhibitors (PARPi). A subset of HR-proficient ovarian tumors show amplification in bromodomain and extra-terminal (BET) genes such as BRD4. We aimed to test the hypothesis that BRD4 inhibition sensitizes ovarian cancer cells to PARPi by reducing HR efficiency and increasing DNA damage. METHODS: HR-proficient ovarian cancer cell lines (OVCAR-3, OVCAR-4, SKOV-3, UWB1.289+BRCA1) were treated with BRD4-targeting siRNA, novel (INB054329, INCB057643) and established (JQ1) BET inhibitors (BETi) and PARPi (olaparib, rucaparib). Cell growth and viability were assessed by sulforhodamine B assays in vitro, and in SKOV-3 and ovarian cancer patient-derived xenografts in vivo. DNA damage and repair (pH2AX, RAD51 and BRCA1 foci formation, and DRGFP HR reporter activity), apoptosis markers (cleaved PARP, cleaved caspase-3, Bax) and proliferation markers (PCNA, Ki67) were assessed by immunofluorescence and western blot. RESULTS: In cultured cells, inhibition of BRD4 by siRNA or INCB054329 reduced expression and function of BRCA1 and RAD51, reduced HR reporter activity, and sensitized the cells to olaparib-induced growth inhibition, DNA damage induction and apoptosis. Synergy was observed between all BETi tested and PARPi. INCB054329 and olaparib also co-operatively inhibited xenograft tumor growth, accompanied by reduced BRCA1 expression and proliferation, and increased apoptosis and DNA damage. CONCLUSIONS: These results provide strong rationale for using BETi to extend therapeutic efficacy of PARPi to HR-proficient ovarian tumors and could benefit a substantial number of women diagnosed with this devastating disease.
引用
- Wilson AJ, Stubbs M, Liu P, et al. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Gynecol Oncol. 2018. PMID: 29567272. doi:10.1016/j.ygyno.2018.03.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。